Influence of propranolol on weight and salt and water homoeostasis in chronic liver disease.
Sixteen patients with chronic liver disease were treated with propranolol or placebo in a double-blind study. Skinfold thickness, total body water and exchangeable sodium, and urinary sodium were measured every 6 months for a year; body weight was measured every 2 (later every 3) months for 15 months. Propranolol treatment was associated with a significant rise in body weight after 9 months and significant rises in skinfold thickness and body fat after 12 months. Propranolol-treated patients showed a fall in total body water at 6 months and a rise in urinary sodium concentration at 12 months. They did not show the rise in total body exchangeable sodium that occurred in placebo-treated patients. Propranolol seems to affect salt and water homoeostasis favourably in patients with chronic liver disease.